Breast Cancer

Camizestrant significantly extended PFS compared with fulvestrant among certain postmenopausal patients with advanced breast cancer, according to the agent’s manufacturer.

The addition of capivasertib to fulvestrant significantly extended PFS among patients with advanced hormone receptor-positive breast cancer, according to topline data released by the agent’s manufacturer.

Research published in The Journal of Clinical Endocrinology & Metabolism highlighted the need for better evidence on long-term health consequences of gestational diabetes.

In this video, Erica L. Mayer, MD, MPH, discusses important takeaways from breast cancer sessions at this year’s European Society for Medical Oncology Congress.

Adjuvant palbociclib combined with endocrine therapy failed to extend invasive DFS compared with endocrine therapy alone among patients with stage IIA hormone receptor-positive, HER2-negative breast cancer, according to study results.

Previous research has demonstrated associations between nutrition and breast cancer.

GENEVA — Remote interventions led to higher screening rates for breast, cervical and colorectal cancers among women who live in rural areas, according to study results presented at World Cancer Congress.

GENEVA — Women who used low-dose aspirin did not exhibit reduced risk for breast cancer, according to study results presented at World Cancer Congress.

A fourth dose of the COVID-19 vaccine increased humoral immunity among patients with solid and hematologic cancers, according to study results published in JAMA Oncology.

The benefits of gender-affirming hormone therapy outweigh the risks for transgender women of all ages as well as those with comorbidities, according to a speaker at the 2022 North American Menopause Society annual meeting.